Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41


Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Jung YY, Hyun CL, Jin MS, Park IA, Chung YR, Shim B, Lee KH, Ryu HS.

J Breast Cancer. 2016 Sep;19(3):261-267.


Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis.

Shen YW, Zhang XM, Lv M, Chen L, Qin TJ, Wang F, Yang J, Liu PJ, Yang J.

Onco Targets Ther. 2015 Nov 13;8:3349-59. doi: 10.2147/OTT.S95936.


ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.

Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwartz NS, Lager E, Fornander T, Nordenskjöld B, Yu JJ, Stål O, Holz MK.

Clin Cancer Res. 2016 Mar 15;22(6):1421-31. doi: 10.1158/1078-0432.CCR-15-0857.


Management of early breast cancer in older women: from screening to treatment.

Elomrani F, Zine M, Afif M, L'annaz S, Ouziane I, Mrabti H, Errihani H.

Breast Cancer (Dove Med Press). 2015 Jul 7;7:165-71. doi: 10.2147/BCTT.S87125. Review.


Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Freedman OC, Fletcher GG, Gandhi S, Mates M, Dent SF, Trudeau ME, Eisen A.

Curr Oncol. 2015 Mar;22(Suppl 1):S95-S113. doi: 10.3747/co.22.2326. Review.


Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Gandhi S, Fletcher GG, Eisen A, Mates M, Freedman OC, Dent SF, Trudeau ME.

Curr Oncol. 2015 Mar;22(Suppl 1):S82-94. doi: 10.3747/co.22.2321. Review.


Tamoxifen prevents apoptosis and follicle loss from cyclophosphamide in cultured rat ovaries.

Piasecka-Srader J, Blanco FF, Delman DH, Dixon DA, Geiser JL, Ciereszko RE, Petroff BK.

Biol Reprod. 2015 May;92(5):132. doi: 10.1095/biolreprod.114.126136.


Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study.

Vale CL, Rydzewska LH, Rovers MM, Emberson JR, Gueyffier F, Stewart LA; Cochrane IPD Meta-analysis Methods Group..

BMJ. 2015 Mar 6;350:h1088. doi: 10.1136/bmj.h1088.


Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.

Miller E, Lee HJ, Lulla A, Hernandez L, Gokare P, Lim B.

F1000Res. 2014 Aug 19;3:198. doi: 10.12688/f1000research.4340.1. Review.


HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.

Abdel-Fatah TM, McArdle SE, Johnson C, Moseley PM, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Br J Cancer. 2014 May 13;110(10):2450-61. doi: 10.1038/bjc.2014.168.


EP1: a novel rabbit monoclonal antibody for detection of oestrogen receptor α.

Badve S, Vladislav IT, Spaulding B, Strickland A, Hernandez S, Bird-Turner L, Dodson C, Elleby B, Phillips T.

J Clin Pathol. 2013 Dec;66(12):1051-7. doi: 10.1136/jclinpath-2012-201391.


Treatment of breast cancer in young women: do we need more aggressive therapies?

Cancello G, Montagna E.

J Thorac Dis. 2013 Jun;5 Suppl 1:S47-54. doi: 10.3978/j.issn.2072-1439.2013.06.10.


Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.

Brooks JD, Teraoka SN, Bernstein L, Mellemkjær L, Malone KE, Lynch CF, Haile RW, Concannon P, Reiner AS, Duggan DJ, Schiermeyer K; WECARE Study Collaborative Group., Bernstein JL, Figueiredo JC.

Cancer Causes Control. 2013 Aug;24(8):1605-14. doi: 10.1007/s10552-013-0237-6.


Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention.

Mandelblatt J, van Ravesteyn N, Schechter C, Chang Y, Huang AT, Near AM, de Koning H, Jemal A.

Cancer. 2013 Jul 15;119(14):2541-8. doi: 10.1002/cncr.28087.


Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model.

Franci C, Zhou J, Jiang Z, Modrusan Z, Good Z, Jackson E, Kouros-Mehr H.

PLoS One. 2013;8(3):e58183. doi: 10.1371/journal.pone.0058183.


A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, Roumen RM, Knauer M, van 't Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC.

Int J Cancer. 2013 Aug 15;133(4):929-36. doi: 10.1002/ijc.28082.


Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study.

Recchia F, Candeloro G, Desideri G, Necozione S, Recchia CO, Cirulli V, Rea S.

Cancer Med. 2012 Aug;1(1):89-95. doi: 10.1002/cam4.3.


Weight-based chemotherapy dosing in obese patients with cancer: back to the future.

Lyman GH.

J Oncol Pract. 2012 Jul;8(4):e62-4. doi: 10.1200/JOP.2012.000606. No abstract available.


Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality.

Chang Y, Schechter CB, van Ravesteyn NT, Near AM, Heijnsdijk EA, Adams-Campbell L, Levy D, de Koning HJ, Mandelblatt JS.

Breast Cancer Res Treat. 2012 Dec;136(3):823-35. doi: 10.1007/s10549-012-2274-3.

Items per page

Supplemental Content

Support Center